Whereas an estimated 78,980 new cases of primary and non-malignant tumors in the brain and central nervous system are expected to be diagnosed in the United States during calendar year 2018; Whereas up to 500,000 individuals were diagnosed with metastatic brain tumors that were the result of cancer spreading from another part of the body to the brain in 2016; Whereas pediatric brain tumors are the leading cause of death from cancer in children under the age of 19; Whereas the average survival rate in the United States for all malignant brain tumor patients is only 34.9 percent; Whereas an estimated 16,616 people in the United States will lose their battle with a primary brain tumor during calendar year 2018; Whereas brain tumors may be malignant or benign, but can be life-threatening in either case; Whereas nearly 700,000 people in the United States are currently living with a brain tumor; Whereas treatment of brain tumors is complicated by the fact that there are more than 130 different types of tumors; Whereas the treatment and removal of brain tumors present significant challenges because of the uniquely complex and fragile nature of the brain; Whereas brain tumors affect the primary organ in the human body that not only controls cognitive ability, but the actions of every other organ and limb in the body, leading to brain tumors being described as a disease that affects the whole individual; Whereas brain tumor research is supported by a number of private, nonprofit research foundations, and by institutes at the National Institutes of Health, including the National Cancer Institute and the National Institute for Neurological Disorders and Stroke; Whereas basic research advances may fuel research and development of new treatments for brain tumors; Whereas there remain challenging obstacles to the development of new treatments for brain tumors, and there are no strategies for screening or early detection of brain tumors